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Objective: Diabetes mellitus, as a risk factor for endometrial cancer (EC), causes an increase in insulin and IGF-1
concentrations in the blood serum. The increase in insulin and IGF-1 are considered mitogenic factors contributory
to cancer development. Studies suggest that metformin has preventive activity, decreasing mortality and the risk of
neoplasms. Since estrogen (ER), progesterone (PR) and IGF-1 (IGF-1R) receptor expression and β-catenin and PAX-2
mutations are significant in the development of endometrial cancer, it was decided to study these factors in
patients with endometrial cancer and type 2 diabetes mellitus (DM2), and to establish the effects of metformin
on their expression.
Methods: The expression of ER, PR, IGF-1R, β-catenin and PAX-2 have been immunohistochemically investigated in
86 type I endometrial cancer specimens. Patients were grouped according to the presence of DM2 and the type of
hypoglycemic treatment administered.
Results: Comparing EC patients with DM2 and normal glycemic status, we found increased IGF-1R expression in
women with DM2. A decrease in ER expression was noted in women with EC and DM2 receiving metformin as
compared to women treated with insulin (p = 0.004). There was no statistically significant difference in PR, IGF-1R,
β-catenin and PAX-2 expression among women receiving metformin and other hypoglycemic treatment.
Conclusion: Although epidemiological studies suggest the beneficial role of metformin in many human cancers,
there are still few studies confirming its favorable effect on endometrial cancer. Decreased ER expression in patients
receiving metformin needs further research to allow evaluation of its clinical significance.
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Endometrial carcinoma (EC) is the sixth most commonly
diagnosed cancer in women [1]. Risk factors for developing
EC type 1, according to Bokhman division, are: imbalanced
estrogen-progesterone ratios, advanced age, nulliparity,
tamoxifen therapy, diabetes mellitus and obesity.
Among the women diagnosed with endometrial carcin-
oma, only 20-30% present normal body weight. Diabetes
mellitus and surplus fat tissue are conducive to excessive
androgen production and its peripheral conversion to* Correspondence: monika@pawalowska.pl
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distribution, and reproduction in any mediumestrone via aromatase. This mechanism is enhanced by
hyperinsulinemia and IGF-1 overproduction, resulting
in PI3K/Akt and MAPK pathway activation and conse-
quently in increased cell division. An increased concen-
tration of IGF-1 is linked to a decrease in sex hormone
binding globulin (SHBG) production in the liver. Under
normal circumstances, SHBG binds estrogens lowering
their serum free fractional concentration, whereas
decreased SHBG production increases the number of
active hormones. Estrogen, not balanced by gestagen
activity, stimulates endometrial cell proliferation, e.g.
via local IGF-1 production, leading to endometrial
hyperplasia and eventually to EC [2-4].tral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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widely used antidiabetic drug. Population studies show
that metformin significantly reduces cancer risk in
diabetic patients. A comparison of metformin patients
with those taking sulfonylurea derivatives shows a 23%
decrease in incidence of malignant neoplasms [5].
Metformin also lowers the risk of death from cancer.
In a five-year observation period of 10,309 DM2
patients, a significant reduction in cancer mortality
was noted among those on metformin when compared
to patients on sulfonylurea derivatives or insulin (3.5%
vs 4.9% vs 5.8%) [6], - esophageal, liver, colorectal, pan-
creatic, breast and lung cancers having the greatest risk
reduction [7,8]. Recent studies have showed that metfor-
min can inhibit cell proliferation and induce apoptosis
in endometrial cancer cell lines [9].
The mechanism of metformin action is complex, all
processes ultimately lead to enhanced tissue insulin
sensitivity and reductions in blood glucose and insulin
levels. The basic mechanism of metformin is to activate
serine-threonine kinase (AMPK), a key protein in sustain-
ing proper cell energy management. Metformin activates
AMPK indirectly via a suppressor protein, liver kinase
B1 (LKB1), and via the activation of tuberous sclerosis
complex 2 (TSC-2) which inhibits the mammalian target
of rapamycin (mTOR) protein, one of the key proteins
in regulating cell division, protein synthesis, growth
and angiogenic processes [10,11].
The mTOR protein is activated via the PI3K/Act path-
way induced by insulin and growth factors, i.e.: IGF-1,
EGF, PDGF and VEGF. High levels of insulin and IGFs in
patients with DM2 and EC are contributive to mTOR
overexpression, increased cell proliferation and resistance
to apoptosis [12].
Additionally to the established role of estrogen and
progesterone in hyperplasia induction and endometrial
cancer onset, are other factors also involved in the
development of this cancer, which include IGF-1R, β-
catenin and PAX-2.
IGF-1 is a polypeptide produced in the liver similar
in structure and function to insulin. After binding to its
receptor (IGF-1R), signaling may occur through differ-
ent mediators, the dominant pathway being PI3K/Akt,
but also the MAPK (mitogen activated protein kinase)
pathway. In the uterus, IGF-1 expression is strictly regu-
lated by estrogen. Its signaling system is essential for
cell differentiation, proliferation and migration. IGF-1
overexpression leads to neoplastic transformation, cancer
progression and metastasis [13,14]. While examining
the expression of IGF-1R in 152 cancers of various sites
of origin, Ouban et al. [13] demonstrated high receptor
membrane expression in breast cancer with prevalence
of 87.5%, and of the ovary and endometrium with
prevalence of 100%.β-Catenin with E-cadherin play a role in preserving
proper tissue architecture through the regulation of
intercellular adhesion. Moreover, it constitutes part of
the Wnt pathway that participates in the control of the
expression of genes responsible for the normal course
of the cell cycle, as well as for proliferation and for
apoptosis. Mutations leading to the Wnt pathways
excessive activation, are found in many malignant neo-
plasms including EC. Numerous studies show that β-
catenin mutations may be crucial for carcinogenesis
[15,16]. Because the studies evaluating β-catenin expres-
sion in the presence of DM2 are limited, we have decided
to investigate if DM2 and its method of treatment change
the role of β-catenin in EC.
The PAX-2 gene encodes the transcript proteins in-
volved in cell proliferation, differentiation and apoptosis.
Mutations in these genes may result in modulation of
the respective genes, thus contributing to oncogenesis
[17,18]. A relationship between lowered PAX-2 expression
and ovarian cancer, endocervical adenocarcinoma and EC
was described [19,20]. Recently, two PAX-2 isoforms
(PAX-2A and PAX-2B) have been discovered in pancreatic
islets of Langerhans cells, one of their roles is to activate
the glucagon gene expression responsible for the pro-
duction of this hormone [21].
Since estrogen, progesterone and IGF-1 receptor ex-
pression is significant in EC, and mutations in β-catenin
and PAX-2 genes seems to be crucial in the neoplastic
transformation of the endometrium, it was decided to
study these factors in women with combined EC and
DM2, and to determine a preventive effect of metformin
on their expression.
Methods
The study is multicentric and of retrospective character.
The material consists of 150 archived samples of post-
menopausal woman with type I endometrial cancer
(endometrioid type) operated between 2007 and 2012.
Patients with previous chemotherapy or radiotherapy
were excluded.
All the samples were re-examined by H&E staining,
from which 86 were stained immunohistochemically (IHC)
(24 samples were excluded due to insufficient cancerous
material, 15 – advanced autolysis, 2- premenopausal
patients, 8- serous/clear cell carcinoma, 15- lack of proper
documentation).
EC patients were divided in two groups according to
the presence of DM2 – 48 DM2 subjects and 38 non-
diabetic subjects (control group). Among the patients
with DM2, 32 were treated with metformin in polytherapy
(n = 10) or monotherapy (n = 22), the other 16 patients
used insulin or sulfonylurea derivatives. Due to small
number of patients receiving sulfonylurea derivatives in
monotherapy (n = 6) we analyzed this subgroup together
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acteristics and the type of hypoglycemic drug used are
shown in Tables 1 and 2.
This study was approved by the Ethics Committee of
the Poznan University of Medical Sciences.
The average age of the patient with EC was 65.25. Pa-
tients with EC and DM2 were older than the EC control
group (67.2 vs 62.8 p = 0.01). The average BMI in all of
the EC patients was 32.1 kg/m2. Patients with EC and
DM2 had a higher BMI index than EC patients without
diabetes (33.6 vs 30.5 p = 0.01). In relation to the methods
of anti-diabetic treatment, there was no difference in the
average age and BMI of DM2 cancer patients.
In order to assess the relationship between protein
expression and the FIGO stage of EC, the patients were
divided into two subgroups- FIGO I and FIGO II-IV
stages.
A total of 86 preparations were IHC stained to deter-
mine the presence of ER (clone SP1), PR (clone 636),
IGF-1R (clone G11) (Ventana Medical Systems, Inc), β-
catenin (clone 14) (Dako Denmark) and PAX-2 (clone
3C7) (AbD Serotec). IHC analysis was performed using
the UltraView DAB Detection Kit system by Roche Group.
Immunoperoxidase staining was performed using the
Ventana BenchMark Ultra.
The nuclear receptor expression was assessed by count-
ing point values (SCORE) equal to the sum of average
intensity of positive-staining cancer cells (scale from 0
to 3, where 0 stands for no, 1- weak, 2- intermediate,
3- strong intensity of staining) and the percentage of
stained cells (scale from 0 to 5; 0- none; 1- < 1%; 2- 1%-
10%; 3- 10%-33.3%; 4–33.3%-66.6% and 5- >66.6%) [22].
For proteins that displayed a membranous reaction, only
the percentage of positively stained cells (from weak to
strong intensity of staining) in the cancer tissue were
determined (FIELD).
The assessment was performed by two separate in-
vestigators in blinded fashion, each person scored the
staining in ten HPFs (high power fields). Due to a sub-
stantial number of samples stained, the batch analysis
was carried out by comparison of staining intensity of




Metformin + other drugs Insulin in m
(n = 22) (n = 10) (n =
FIGO I 19 9 8
FIGO II-IV 3 1 2
G1 8 6 6
G2 13 3 3
G3 1 1 1In statistical calculations, Mann-Whitney’s and Spearman’s
tests were used (STATISTICA, StatSoft Inc, USA). Statistical
significance was set at a p value < 0.05.Results
Table 3 represents mean percentage values of IHC positively
stained cells for ER, PR, PAX-2, IGF-1R and β-catenin in
studied groups. ER, PR and PAX-2 demonstrated a nuclear
type of reaction (Figures 1, 2, 3). IGF-1R staining was
of a membranous type (Figure 3). β-catenin demonstrated
two staining patterns: one being nuclear and the other a
dominant, membranous reaction (Figure 4).ER
In our material, although we observed decreasing expres-
sion of ER parallel with decreasing histological differenti-
ation of cancer cells, we did not find statistically significant
difference in ER expression according to the grade of EC
(G1 vs G2 p = 0.99; G2 vs G3 p = 0.14; G1 vs G3 p = 0.13).
No correlation with FIGO staging was observed. No differ-
ence in the positive ER rate was found when comparing
diabetic and non-diabetic subgroups of the EC patients
(p = 0.18). However, it was shown that DM2 women with
EC receiving insulin in monotherapy had a significantly
higher ER expression than non-diabetic women with EC
(p = 0.0046).
Moreover, patients treated with metformin demonstrated
a statistically significant reduction in ER expression in
comparison to the group receiving insulin in monother-
apy (p = 0.014 for all patients treated with metformin;
p = 0.004 for metformin in monotherapy) (Figure 5).PR
Comparing EC of low and high grade, a reduced PR
expression was found in samples with poorly differen-
tiated cells (G1 vs G3 p = 0.029; G1 vs G2 and G2 vs
G3 p > 0.05). However, no differences were observed in PR
expression in relation to FIGO staging, the presence of
diabetes, and the method of its treatment (p > 0.05).of hypoglycemic drug
ncer (n = 86)
onotherapy Sulfonylurea derivatives Non- diabetics (control)






Table 2 Detailed patient characteristics (age, FIGO stage, grading) and type of hypoglycemic drug
No D.t2 Drug Age FIGO Grading No D.t2 Age FIGO Grading
1 + Met 60 IA G2 1 - 58 IA G1
2 + Met 61 IB G1 2 - 61 IB G2
3 + Met 57 IA G1 3 - 43 IA G1
4 + Met 63 IA G1 4 - 73 IA G1
5 + Met 73 IA G2 5 - 59 II G2
6 + Met 62 IB G1 6 - 63 IA G1
7 + Met 63 II G2 7 - 56 IA G1
8 + Met 74 IB G2 8 - 59 IA G2
9 + Met 74 IA G1 9 - 52 IA G1
10 + Met 73 IA G1 10 - 61 IA G1
11 + Met 69 IB G2 11 - 55 IB G1
12 + Met 60 IA G2 12 - 63 IB G2
13 + Met 71 II G2 13 - 70 IA G2
14 + Met 68 IA G2 14 - 62 IA G1
15 + Met 72 IB G1 15 - 54 IA G1
16 + Met 58 IB G2 16 - 56 IA G1
17 + Met 80 II G2 17 - 76 IIIA G3
18 + Met 57 IB G3 18 - 65 II G2
19 + Met 71 IA G1 19 - 52 IA G1
20 + Met 78 IB G2 20 - 69 IA G1
21 + Met 65 IA G2 21 - 71 IA G2
22 + Met 76 IA G2 22 - 80 II G1
23 + Met + Ins 61 IB G3 23 - 67 IA G2
24 + Met + Ins 54 IA G1 24 - 58 IV G2
25 + Met + Ins 80 IA G1 25 - 56 IIIA G3
26 + Met + Ins 72 IA G2 26 - 71 IB G2
27 + Met + Ins 73 IB G1 27 - 59 IB G1
28 + Met + Ins 71 IVB G1 28 - 71 IB G1
29 + Met + Ins 64 IA G2 29 - 59 IB G3
30 + Met + Ins 69 IA G2 30 - 68 IA G1
31 + Met + Ins 61 IA G1 31 - 65 IB G1
32 + Met + Sulf 58 IA G1 32 - 71 IB G2
33 + Ins 68 IB G1 33 - 66 IB G1
34 + Ins 66 IA G1 34 - 59 IB G3
35 + Ins 74 IIIB G3 35 - 76 IB G1
36 + Ins 76 IB G2 36 - 52 IA G1
37 + Ins 72 II G1 37 - 76 IB G1
38 + Ins 69 IA G2 38 - 54 IB G1
39 + Ins 73 IA G2
40 + Ins 61 IA G1
41 + Ins 72 IA G1
42 + Ins 63 IB G1
43 + Sulf 55 IA G2
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Table 2 Detailed patient characteristics (age, FIGO stage, grading) and type of hypoglycemic drug (Continued)
44 + Sulf 63 IA G1
45 + Sulf 50 IB G1
46 + Sulf 72 IB G2
47 + Sulf 61 IA G1
48 + Sulf 83 IB G2
D t.2- diabetes type 2; Met- metformin; Ins- insulin; Sulf- sulfonylurea derivatives.
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No difference in the rate of positively stained cells was
found in the EC group in relation to grading and FIGO
staging.
Cancer patients with diabetes showed a significantly
higher IGF-1R expression then the non-diabetic group
(p = 0.0012). This trend is present in groups of women
treated with metformin (p = 0.0056) or other drugs
(p = 0.01). Comparing different types of anti-diabetic
treatments in EC patients, we did not find any significant
changes in the expression of IGF-1R (p > 0.05).β-Catenin
All cases under study, excluding one (a case of FIGO IIIA
G3 endometrioid cancer in a non-diabetic patient with
a strong nuclear reaction) demonstrated a dominant,
membranous reaction of β-catenin.
The group of diabetic EC patients did not show a
difference in membranous protein expression in com-
parison to the control groups (p = 0.32). No differences
were demonstrated in relation to cancer grading or clinical
advancement of the disease according to FIGO (p > 0.05).
However, although not statistically significant, patients
on metformin monotherapy displayed a lower protein
expression than those on insulin monotherapy (p = 0.07).
A nuclear reaction was found in 12 out of 86 EC samples
(13.9%), 8 cases concerning non-diabetic and 4 cases
concerning diabetic patients (8.3% and 21.5%, respectively
for each group). Among diabetic patients, two cases were
treated with metformin and two with insulin or sulfonyl-
urea derivatives. Positive nuclear staining was found atTable 3 Mean percentage (± SD) of positive immunohistochem
SCORE results (ER, PR and PAX-2) in patient subgroups
PR score ER score
EC + diabetes (n = 48) 6.85 ± 1.76 6.91 ± 1.51
M in mono- and polytherapy (n = 32) 6.78 ± 2.01 6.71 ± 1.67
M in monotherapy (n = 22) 6.86 ± 1.83 6.77 ± 1.15
I + SD (n = 16) 7.0 ± 1.15 7.31 ± 1.07
I in monotherapy (n = 10) 7.1 ± 1.28 7.8 ± 0.42
Control (n = 38) 6.39 ± 2.23 6.28 ± 2.17
EC- endometrial cancer, M- metformin, I- insulin, SD- sulfonylurea derivatives, I + SD
therapy (n = 6) we have analyzed this subgroup together with patients treated withboth early and advanced stages of the disease and with
low and high grade differentiation (Table 4).
PAX-2
The intensity of the nuclear reaction for PAX-2 was not
statistically varied between DM2 EC patients and control
groups (p = 0.53). No differences were observed between
FIGO staging and grading, and the type of anti-diabetic
drug administered (p > 0.05).
Discussion
ER, PR, IGF-1R
The increased risk of developing EC in women with DM2
is an indisputable fact [23]. There is also clear evidence
showing a positive association between the increased
levels of circulating insulin and the incidence of endo-
metrioid adenocarcinoma [24,25]. But despite numerous
studies, there is still no unanimous data explaining the
role of IGF-1 on endometrial carcinogenesis. Additionally,
there is also a lack of consensus on the prevailing type of
receptor (IR or IGF-1R) acting on EC promotion.
Endometrial cancer type I is a hormone dependent
malignant disease, in which the balance between estrogen
and progesterone is disrupted and an increase of estrogen
stimulation leads to excessive cell proliferation.
High ER and PR expression in EC are frequently con-
nected with endometrioid type of neoplasm, better cells
differentiation, lower risk of lymph node metastases and
better prognosis [26,27]. Based on studies of endometrial
and breast cancer tissue, we can observe a profound
and complex crosslink between estrogen, progesterone,
insulin or IGF-1 and its receptors.ically stained cells (IGF-1R and β-catenin) and mean
PAX-2 score IGF-1R β-catenin (membranous)
3.58 ± 2.42 36.79 ± 26.73 86.87 ± 19.17
3.37 ± 2.41 36.59 ± 24.49 83.75 ± 21.28
3.5 ± 2.64 36.41 ± 26.16 84.54 ± 20.23
4.37 ± 2.02 37.18 ± 31.72 93.12 ± 12.36
4.2 ± 2.34 33.5 ± 28.96 97.0 ± 6.32
3.34 ± 2.31 18.29 ± 27.27 87.5 ± 24.40
- Due to small number of patients receiving sulfonylurea derivatives in mono-
insulin.
Figure 1 Different intensities of nuclear immunostaining for ER. A- no; B- weak; C- intermediate, D- strong intensity of staining.
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proliferative phase, estrogen binding to ER receptor acts
as a transcription factor triggering local IGF-1 production
[28]. On the other hand, endometrial stromal cells, due
to progesterone induction, produce IGFBP-1 (IGF-1
binding protein), which after binding to IGF-1 reduces
its bioavailable fraction. Mitogenic function of IGF-1
may occur through different mediators, the dominant
pathway being PI3K/Akt, but also MAPK, both involved
in regulation of cell proliferation and apoptosis. Further-
more, active MAPK signaling can phosphorylate serine
in NH2-terminal region of the ER- AF1, and thereby
increase ER activation [29]. Estrogen not only influences
IGF-1 production but also takes part in the regulation
of IGF-1R, elevating its endometrial expression [30].
The inhibition of IGF-1R promotor may occur via e.g.
p53 [31], but its mutation is often seen in EC leading to
IGF-1R overexpression.
High IGF-1 plasma concentrations and the presence of
IGF-1R on the cell surface are found in many cancers
[32,33], but in the case of EC, the role of circulating
IGF-1 is controversial. It was noted that high fasting
glucose levels in women not on hormone therapy was
correlated with the development of endometrioid adeno-
carcinoma, whereas the rise in free IGF-1 plasma fraction,
has no effect or even decreases the risk of developing
EC [24,34]. These observations may suggest the dominant
role of the local production of IGF-1 in the neoplastic
endometrium. Most likely, the rise of local free IGF-1 in
diabetic patients is due to insulin mediated inhibition of
the production of IGFBP-1 [35].Figure 2 Different intensities of nuclear immunostaining for PR. A- noIn EC tissue, IGF-1 can influence PR expression. Its
high levels are associated with improved prognosis and
response to gestagen treatment, especially in advanced
or recurrent carcinoma [36]. Xie et al. [37] observed
IGF-1 and IGF-2-induced reduction of PR in EC cell
lines, which was related to the activation of the PI3K/
Akt/mTOR pathway and phosphorylation of the p70S6K
effector protein. In an in vitro study, metformin was found
to inhibit the growth of ECC-1 and Ishikawa EC cells
in a dose dependent manner via activation of AMPK and
inhibition of mTOR [9]. It was noted that the adminis-
tration of this drug can raise PR expression in EC [37].
Similar results were presented by Berstein et al. [38] in
90 breast cancer samples from patients with DM2. In
immunohistochemical assessment of ER and PR researchers
found no difference in the ER expression of cancer cell
in women receiving metformin, insulin, sulfonylurea
derivatives and those who were exclusively on a diabetic
diet. However, an increased percentage of positive PR in
breast cancer specimens was found in patients treated
with metformin mono- or polytherapy (p = 0.04).
Our study does not show any difference between PR
expression in patients receiving different types of pharma-
cotherapy in DM2. However, we found a reduction in
the rate in which cells displayed a strong ER reaction in
EC patients receiving metformin in comparison to those
patients on insulin monotherapy. It is believed that
metformin may decrease estrogen concentration in neo-
plastic tissue via local inhibition of aromatase activity
suppressing synthesis of the enzyme through interaction
with its promoter, PII [39]. But the exact mechanism; B- weak; C- intermediate, D- strong intensity of staining.
Figure 3 Nuclear immunostaining for nuclear PAX-2 (A) and IGF-1R membranous type of staining (B).
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We can speculate that the reduction of ER after metfor-
min treatment may decrease the number of cells sensitive
to high levels of estrogens, affecting their proliferative abil-
ities and at the same time may influence the prognosis.
But further studies are needed to confirm this hypothesis.
Pengchong H and Tao H. [40] showed a greater IGF-
1R expression in EC than in normal endometrium and
indicated a correlation between IGF-1R overexpression
and metastasis to the lymph nodes. Roy et al. [41] in
turn found no statistically significant differences between
the amount of mRNA IGF-1R in normal cells and EC
cells. Interestingly, there was a significant reduction in
IGF-1 expression in EC when comparing the endometrium
at proliferative (p = 0.0078) and early secretory (p = 0.0002)
phases. This disproportion between a relatively high
IGF-1R and low IGF-1 in EC cells may reflect intense
disruptions in IGF-1R encoding gene expression, leading
to protein overproduction (e.g. mutations in suppressor
genes i.e. p53 or BRCA1 resulting in the lack of inhibitory
effect on the IGF-1R promotor).
In our material women with EC and diabetes dem-
onstrated a significantly higher IGF-1R expression in
comparison to the non-diabetic women. This may be
associated with e.g. different affinity to specific receptors
(IR- α and β, IGF-1R, hybrid receptors) of insulin, and the
circulating IGF-1 and IGF-2 or their local production
in neoplastic tissue. Metformin administration did not
significantly influence the number of IGF-1R in EC.
Presumably, the drug inhibits further stages of theFigure 4 Membranous (A) and nuclear (B) type of immunostaining foPI3K/Akt/mTOR pathway initiated by IGF-1R, without
direct influence on IGF-1R membrane expression. In
future research it is valid to compare the expression
and activity not only of IGF-1R but also of IR isoforms
in normal and neoplastic endometrium of diabetic and
non-diabetic patients and to assess the influence of
metformin on their expression.
Beta-catenin
β-Catenin (CTNNB1) plays a double role in cells –first, it
regulates cellular adhesion via interaction with membrane
protein E-cadherin – second, in the cell nucleus it plays a
key role in the Wnt signaling pathway.
The normal endometrium displays a strong membranous
reaction of β-catenin. However, a reduction in β-catenin
and E-cadherin expression is noted in different types of
neoplastic tissue, including endometrial tissue. Seagusa
et al. [42] revealed a gradual decrease in cell membrane
β-catenin immunoreactivity from normal to atypical
hyperplasia and to grade 3 carcinomas. Disruption in
both β-catenin and E-cadherin expression is associated
with reduced cell to cell adhesion, the advancement of
the clinical stage of the disease and the increased risk
of metastasis [15,16].
The Wnt signaling pathway is a multi-protein complex
consisting of axins, β-catenin, APC (adenomatous polyposi
coli), kinase CKI (casein kinase I) and GSK3β (glycogen
synthase 3β). In the absence of Wnt ligands, the APC/
GSK3β/Axin complex is activated which results in phos-
phorylation of β-catenin and its ubiquitination andr β-catenin.
Figure 5 ER expression (score) in endometrial cancer cells according to presence of diabetes and method of its treatment. M- metformin,
I- insulin, SD- sulfonylurea derivatives.
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activated, APC/GSK3β/Axin does not form a complex
with β-catenin and phosphorylation of this protein is
inhibited. Stabilized β-catenin is translocated to the
nucleus and is assembled into a complex with tran-
scription factors LEF (lymphoid enhancer factor) and
TCF (T-cell factor), promoting expression of many genes
involving in cell proliferation (Myc or cyclin D1), angio-
genesis (VEGF), adhesion and apoptosis (survivin).
Activation of β-catenin/Wnt pathway is a physiological
phenomenon during the menstrual cycle, but it differs
among cycle phases. Nei et al. [43] showed the presence
of nuclear β-catenin in the proliferative phase, whereas
during the secretory phase the protein was found mainly
in the cytoplasm and the cell membrane.
Estradiol can change the expression of the Wnt ligands
including Wnt 4 and 7A [43,44]. Furthermore, it is also
linked to Wnt and PI3k/Akt signaling pathways. It was
found that after estrogen stimulation, ER alpha induced
PI3K and subsequently activated Akt. This in turn re-
sulted in phosphorylation and inhibition of GSK3 [45].Table 4 Nuclear expression of β-catenin according to the pre
its treatment
EC - Total EC DM2 – Metformin EC D
(n = 86) (n = 32)
B-CATENIN 12 (13,9%) 2 (8,3%)
FIGO IA- 4 IA- 1
IB- 5 IB- 1
II- 1 II- 0
IIIA- 2 IIIA- 0
GRADING G1- 4 G1- 1
G2- 5 G2- 0
G3- 3 G3- 1Consequently, β-catenin cannot be phosphorylated and
degraded in proteasomes.
A number of studies indicate disruptions in β-catenin
expression in EC, most frequently in the endometrioid
type. Mutations in CTNNB1, but also in other genes
encoding proteins taking part in Wnt pathway (APC or
axin), result in stabilization of β-catenin, its excessive
nuclear accumulation and promotion of many genes
which lead to neoplastic transformation [46]. Konopka
et al. [47] found mutations in the CTNNB1 region in
16.1% of ECs. The mutations detected at the atypical
hyperplastic endometrium and the early stages of EC
suggest their significant role in early carcinogenesis [44].
Limited literature concerning β-catenin expression in
diabetic EC patients makes it impossible to compare our
findings to other studies. In our material concerning EC,
β-catenin nuclear staining was found in 13.9% of cases
which corresponds accordingly to the Nout et al. research
[48] of 14%. In our findings the majority of cases con-
cerned non-diabetic patients with EC (21.5% vs 8.3% of
patients with diabetes) (Table 3). Due to a small numbersence of endometrial cancer, diabetes and method of
M2 - Insulin or sulfonylurea derivatives EC – Control group
(n = 16) (n = 38)
2 (12,5%) 8 (21,5%)
IA- 0 IA- 3
IB- 2 IB- 2
II- 0 II- 1
IIIA- 0 IIIA- 2
G1- 1 G1- 2
G2- 1 G2- 4
G3- 0 G3- 2
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difficult to assess the influence of anti-diabetic treatment
on nuclear accumulation of β-catenin. However, if met-
formin reduces the expression of ER, which was dem-
onstrated in our study, it is presumed that it may also
decrease the activation of PI3K/Akt signaling, increasing
the unphosphorylated fraction of GSK3 and reducing
the amount of β-catenin. Further studies are necessary
to examine the correlation between β-catenin expression,
Wnt pathway activation and diabetes in women with EC.
PAX-2
PAX-2 participates in regulating the proper development of
the central nervous system, the kidneys and the Müllerian
ducts (upper part of the vagina, uterus, fallopian tubes).
Even more evidence indicates that it also has a significant
role in oncogenesis, including EC.
Monte et al. [20] described the loss of PTEN and PAX-2
expression in normal, hyperplastic, and cancer cells,
indicating that independent from PTEN, PAX-2 acts
as a suppressor gene undergoing inactivation during
cancer transformation. In the normal endometrial tissue,
versus precancerous lesions and cancer, the level of the
PAX-2 protein loss increases progressively at the rate of
36%, 71%, and 77% respectively. Similar results were
obtained by Allison et al. [49], which suggests that PAX-2
protein losses occur at an early stage of carcinogenesis.
Unfortunately the mechanism explaining this phenomenon
is yet unknown.
Researchers do not know of any study regarding PAX-
2 expression in EC in relation to coexisting glucose
tolerance disorders.
In our material, no difference in PAX-2 nuclear expres-
sion was found in patients with EC in relation to the pres-
ence of diabetes or the type of treatment administered.
However, these results may be considered as questionable,
because of the strong staining of the cytoplasm which
may have deterred the assessment of the nuclear reaction.
Further research is needed in order to determine if there
is a relationship between PAX-2 expression and diabetes
in patients with EC, if proven so, then to additionally
determine the influence of metformin administration.
Conclusion
Diabetes as a risk factor in EC increases insulin and
IGF-1 blood levels, both considered mitogenic factors
contributing to the development of many cancers via
enhanced cell proliferation. Many trials as well as ongoing
clinical research suggest a preventive effect of metformin,
not only in the context of malignant neoplasms, but also
as a factor for improved prognosis and reduced mortality
among cancer patients. With the use of immunohisto-
chemical assessment, this research found a reduction in
ER expression in diabetic women receiving metformin.Such relationship was not found for PR. Although, enhanced
IGF-1R expression has been observed in EC of diabetic
patients, no statistically significant difference were found
among patients receiving metformin, insulin or sulfonyl-
urea derivatives. Additionally, no statistically significant
differences have been noted in the β-catenin and PAX-2
reaction for any of the compared groups. Further research
is necessary to assess the effects of the abovementioned
proteins in the prognosis of patients with EC and diabetes
treated with metformin.
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